Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Bad
|
New words:
Acellular, adjunct, Adsorbed, afflicted, Antelliq, Argentina, arm, ASC, ASCO, ASR, ASU, attenuated, auditor, axitinib, basket, BC, Beach, bilateral, birthday, body, border, Burling, Cavatak, ceftolozane, cert, cervical, clause, clawback, clearance, cloud, CNDA, coexistence, colistimethate, colistin, compel, conditionally, conjugate, context, coupon, Covington, CPS, cystectomy, cytotoxic, Czech, Delaware, Delstrigo, depict, diagnosed, directionally, dissolution, docetaxel, drove, ejection, embedded, endometrial, engineered, epidermal, ESMO, esophagogastric, fight, Francisco, Gastrointestinal, gefapixant, Genitourinary, glycaemic, Greece, Hamburg, handed, histology, Hong, immunocompromised, immunodeficiency, Inlyta, insomnia, intolerance, investee, invoice, invoiced, irinotecan, ix, JMHLW, kidney, Kong, leadership, Liaison, lymph, malignant, men, Meningococcal, mesothelioma, metronidazole, Mexican, Mizell, Monsanto, Nally, nephrotoxicity, Nike, NNRTI, node, nosocomial, onset, opt, orexin, Organisation, ORR, outlook, paclitaxel, payback, pet, Pifeltro, pilot, polymorphic, preserved, prompt, pull, rare, reactivation, Rebecca, Republic, resection, retailer, rosuvastatin, Rosuzet, salt, San, satisfied, satisfy, Scalibor, SCLC, shipment, shortly, sickle, sleep, Slovakia, somatic, sorafenib, Sovaldi, spent, Steven, sunitinib, suvorexant, switching, Symposium, tazobactam, toxicity, traceability, unaffected, unbudgeted, undergone, unresponsive, unsettled, vast, verification, vi, viii, vivo, waiting, wrongly, Zaire, ZVex
Removed:
adam, adequately, Aerosol, aforementioned, air, alendronate, Allergan, amortizing, anacetrapib, anticipate, AQ, Aquaculture, Arcoxia, asthma, atypical, austerity, beta, bezlotoxumab, biopharmaceutical, BMS, broadly, buy, Byetta, calcitonin, calendar, cardiac, cessation, CETP, CGRP, chloride, cholesteryl, claimed, collect, collected, consummated, convertible, core, corticosteroid, coupled, Cozaar, declaration, delayed, dental, Department, devaluation, dihydrate, dismissal, Domestically, Dulera, educate, Elkton, ESI, ester, etoricoxib, extending, extraction, farm, federally, focusing, Follistim, follitropin, formalized, Fosamac, Gaynor, healing, heightened, hematological, Hib, holston, hydrochlorothiazide, Hyzaar, impose, influenzae, Inhalation, inhaled, Inspector, Inter, IPR, ipragliflozin, jaw, join, Kotobuki, leave, Lederle, losartan, male, Maryland, mg, mirian, montelukast, Mundipharma, myeloma, nasal, nationwide, NewLink, NGM, Noncompliance, notice, occurring, official, ONJ, Ono, ophthalmology, ordered, peptide, permanently, persistent, polio, positioned, postcombination, potassium, preexisting, principle, printed, proceed, proceeding, proximate, PSC, Puregon, Ratio, recommend, redeemed, refund, rejected, repatriated, requested, requesting, retiree, schechter, sexual, stake, Steering, suffered, supplement, surotomycin, testicular, Teva, tiered, tooth, ulcerative, unaudited, unconditionally, undergoing, unremitted, unspecified, USPTO, Venezuelan, Victoza, VZV, web, whooping, wide, writing, Zuellig
Filing tables
Filing exhibits
- 10-K Annual report
- 10.19 Exhibit 10.19: Merck & Co., Inc. U.S. Separation Benefits Plan (As of 1/1/19)
- 10.27 Exhibit 10.27: Severance Agreement and General Release (Schechter)
- 10.28 Exhibit 10.28: Offer Letter (Zachary)
- 21 Exhibit 21: Subsidiary List
- 23 Exhibit 23: Consent of Independent Registered Public Accounting Firm
- 24.1 Exhibit 24.1: Power of Attorney
- 24.2 Exhibit 24.2: Certification of Board Resolution
- 31.1 Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.1 Exhibit 32.1: Section 1350 Certification of CEO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
Associated MRK transcripts
MRK similar filings
Filing view
External links
Exhibit 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-224016 and 333-224017) and on Form S-8 (Nos. 333-173025, 333-173024, 333‑162882, 333-162883, 333-162884, 333-162885, 333-162886, 333-134281 and 333-121089) of Merck & Co., Inc. of our report dated February 27, 2019 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 27, 2019